Catalog No.: PC-24814Not For Human Use, Lab Use Only.
Ralinepag (APD811) is a potent, selective, orally bioavailable and non-prostanoid prostacyclin receptor (IP) agonist with EC50 of 8.5 nM and 530 nM for human and rat IP receptors respectively, inhibits ADP-induced human platelet aggregation with IC50 of 38 nM.
Ralinepag (APD811) is a potent, selective, orally bioavailable and non-prostanoid prostacyclin receptor (IP) agonist with EC50 of 8.5 nM and 530 nM for human and rat IP receptors respectively, inhibits ADP-induced human platelet aggregation with IC50 of 38 nM. Ralinepag (APD811) has IC50 of 3 nM in radioligand binding assays of affinity for the IP receptor in multiple species, 30- to 50-fold over human EP3, good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family. Ralinepag (APD811) significantly reduce the MCT-induced increase in pulmonary arterial pressure in monocrotaline (MCT) model.
